Condition: Atopic Dermatitis (AD) · Sponsor: Société des Produits Nestlé (SPN)
The main purpose of this study is to assess the efficacy of a partially hydrolyzed formula with synbiotics in halting one of the first steps of the allergic march (atopic dermatitis) in infants at risk of allergy. Other efficacy and safety parameters will be assessed as well.
This description comes directly from the study's public registry record.
Amelie Goyer, PhD · +41217858939 · Amelie.Goyer1@rd.nestle.com
Always discuss trial participation with your own doctor first.
| AZ Sint-Jan Brugge-Oostende AV - Campus Sint-Jan | Bruges, Belgium | Recruiting |
| Universitair Ziekenhuis Brussel - Kinderziekenhuis | Brussels, Belgium | Recruiting |
| Clinique Ste Elisabeth | Namur, Belgium | Recruiting |
| CHU Amiens Picardie | Amiens, France | Recruiting |
| CHU de Caen | Caen, France | Recruiting |
| CHU de Grenoble Alpes | Grenoble, France | Recruiting |
| Hôpital de la Croix Rousse | Lyon, France | Recruiting |
| Hôpital Charles Nicolle | Rouen, France | Recruiting |
| CHRU de Tours | Tours, France | Recruiting |
| Charite-Universitaetsmedizin Berlin - Campus Virchow-Klinikum (CVK) | Berlin, Germany | Not Yet Recruiting |
| Evangelisches Krankenhaus Düsseldorf - Frauenklinik | Düsseldorf, Germany | Recruiting |
| Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Frankfurt | Frankfurt, Germany | Recruiting |
+ 11 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06943469